Related Experiment Video
Updated: May 23, 2026
09:54
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
L-DOPA increases noradrenaline turnover in central and peripheral nervous systems
1Pharmacology Department, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Neuropharmacology
|August 9, 2003
Summary
L-3,4-dihydroxyphenylalanine (L-DOPA) administration increases dopamine levels, which then release noradrenaline (NA) from storage sites. This mechanism was observed in both peripheral and central nervous system neurons, impacting NA efflux.
Area of Science:
- Neuropharmacology
- Neurochemistry
Background:
- L-3,4-dihydroxyphenylalanine (L-DOPA) is a precursor to dopamine and is used to treat Parkinson's disease.
- The precise mechanisms by which L-DOPA influences neurotransmitter release, particularly noradrenaline (NA), are not fully elucidated.
Purpose of the Study:
- To investigate the effect of L-DOPA on noradrenaline (NA) release from peripheral and central nervous system (CNS) neurons.
- To explore the role of dopamine (DA) in mediating L-DOPA-induced NA release.
Main Methods:
- Isolated rat vas deferens experiments with L-DOPA and monoamine oxidase (MAO) inhibitors.
- In vivo frontal cortex microdialysis in rats following L-DOPA administration.
- Measurement of noradrenaline (NA) and dopamine (DA) efflux using various pharmacological interventions.
Main Results:
- L-DOPA increased basal NA efflux in rat vas deferens, but only when MAO-A/B or MAO-B was inhibited.
- L-DOPA increased basal dopamine (DA) efflux in the presence of MAO inhibitors.
- Systemic L-DOPA/carbidopa reduced NA efflux in frontal cortex microdialysis, but increased NA when reuptake was blocked or presynaptic receptors were antagonized.
Conclusions:
- L-DOPA administration leads to increased intraneuronal dopamine (DA) levels.
- Elevated DA levels promote the release of NA from storage vesicles into the cytoplasm.
- This DA-mediated NA release mechanism contributes to the overall neurochemical effects of L-DOPA.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...